It depends what you consider the market.
Kaken basically had 200,000 new patients in the first year, I think BOT will have more.
Not only that. Every BOT patient that renews the script , effectively doubles the patient numbers, since most Japanese on average buy 1 script only. Most americans buy 2.
So although market penetration might oly be 2% or whatever.... if they renew 4 scripts on average.... that is the exquivalent of 4x market penetration in income.
Based on what happened in Japan, it is entirely feasable that the sales in year 1 will be around the 1 billion mark.
Take the same year 1 sales Kaken had, adjust for USA being 3 x the size, and adjust for the fact that USA on average renew 2 scripts where as Japan do not renew. That gives you 900,000 USD in sales ~ or about 1.3 to 1.4 Billion in AUS sales.
The first quarter report will be the first indication of where on that scale we are.
- Forums
- ASX - By Stock
- BOT
- Ann: Trading Halt
Ann: Trading Halt, page-280
-
- There are more pages in this discussion • 111 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
|
|||||
Last
36.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $651.6M |
Open | High | Low | Value | Volume |
36.0¢ | 37.3¢ | 35.3¢ | $1.417M | 3.891M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 110000 | 35.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
36.0¢ | 457035 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 110000 | 0.355 |
7 | 766450 | 0.350 |
5 | 166678 | 0.345 |
13 | 276001 | 0.340 |
3 | 62985 | 0.335 |
Price($) | Vol. | No. |
---|---|---|
0.360 | 451630 | 6 |
0.365 | 238075 | 2 |
0.375 | 601071 | 10 |
0.380 | 275893 | 11 |
0.385 | 412479 | 6 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
BOT (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online